Fortress Biotech Crescita futura

Future criteri di controllo 2/6

Si prevede che Fortress Biotech aumenterà gli utili e i ricavi rispettivamente del 67.3% e 55.9% all'anno, mentre si prevede che l'EPS crescerà del 77.7% all'anno.

Informazioni chiave

67.3%

Tasso di crescita degli utili

77.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	42.4%
Tasso di crescita dei ricavi	55.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	19 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:CNB0 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	240	4	N/A	N/A	1
12/31/2025	136	-36	N/A	N/A	2
12/31/2024	58	-60	N/A	N/A	2
9/30/2024	82	-58	-102	-102	N/A
6/30/2024	83	-49	-100	-99	N/A
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-86	-150	-141	N/A
6/30/2023	63	-104	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	-106	-101	N/A
3/31/2019	27	-53	-105	-96	N/A
12/31/2018	27	-73	-108	-99	N/A
9/30/2018	-107	-61	-107	-98	N/A
6/30/2018	-65	-69	N/A	-98	N/A
3/31/2018	-22	-72	N/A	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A
12/31/2014	N/A	-20	N/A	-16	N/A
9/30/2014	N/A	-26	N/A	-20	N/A
6/30/2014	N/A	-30	N/A	-24	N/A
3/31/2014	N/A	-36	N/A	-28	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CNB0 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CNB0 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CNB0 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CNB0 ( 55.9% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CNB0 ( 55.9% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CNB0 è previsto essere elevato tra 3 anni

Fortress Biotech Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita